Kraig Biocraft Laboratories (KBLB) Common Equity (2010 - 2025)

Kraig Biocraft Laboratories has disclosed Common Equity across 16 years of filings, most recently posting -$8.0 million for Q4 2025.

• Common Equity for Q4 2025 came in at -$8.0 million, up 1.85% year-over-year; the trailing twelve-month figure through Dec 2025 was -$8.0 million (up 1.85% YoY), and the FY2025 annual result was -$8.0 million, up 1.85% from the prior year.
• Common Equity came in at -$8.0 million for Q4 2025 at Kraig Biocraft Laboratories, down from -$8.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$3.5 million in Q4 2022 to a low of -$8.5 million in Q1 2025.
• The 5-year median for Common Equity is -$5.8 million (2021), against an average of -$6.0 million.
• Across the five-year window, Common Equity soared 40.36% in 2022 and tumbled 62.05% in 2023, its largest moves.
• Kraig Biocraft Laboratories' Common Equity stood at -$5.3 million in 2021, then jumped by 33.5% to -$3.5 million in 2022, then tumbled by 62.05% to -$5.7 million in 2023, then sank by 42.8% to -$8.1 million in 2024, then grew by 1.85% to -$8.0 million in 2025.
• The last three Common Equity figures came in at -$8.0 million (Q4 2025), -$8.0 million (Q3 2025), and -$8.5 million (Q2 2025), per Business Quant data.